Sandoz blazes biosimilar trail in Japan
This article was originally published in Scrip
Executive Summary
Sandoz has become the first company to launch a therapeutic biosimilar in Japan with the introduction of Somatropin BS, its version of Pfizer's recombinant human growth hormone Genotropin.